Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 16 2021 - 7:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021
Commission File Number: 001-40712
Cardiol Therapeutics Inc.
(Translation of registrant's name into English)
602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
[ ] Form 20-F [ x ] Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
SUBMITTED HEREWITH
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
CARDIOL THERAPEUTICS INC.
|
|
|
(Registrant)
|
|
|
|
|
|
Date: September 16, 2021
|
By:
|
/s/ Chris Waddick
|
|
|
|
|
|
|
|
Chris Waddick
|
|
|
Title:
|
Chief Financial Officer
|
Cardiol Therapeutics (NASDAQ:CRDL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cardiol Therapeutics (NASDAQ:CRDL)
Historical Stock Chart
From Apr 2023 to Apr 2024
